Edition:
India

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

3.00USD
19 Jan 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.00
Open
$3.00
Day's High
$3.10
Day's Low
$3.00
Volume
30,838
Avg. Vol
31,591
52-wk High
$6.85
52-wk Low
$2.78

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $112.31
Shares Outstanding(Mil.): 24.11
Dividend: --
Yield (%): --

Financials

BRIEF-ProQR And Galapagos Announce Research Collaboration

* PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY

08 Jan 2018

BRIEF-ProQR Receives Orphan Drug Designation From EMA For Drug Candidate Qr-313 For Dystrophic Epidermolysis Bullosa

* PROQR RECEIVES ORPHAN DRUG DESIGNATION FROM EMA FOR DRUG CANDIDATE QR-313 FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

29 Nov 2017

BRIEF-Proqr reports loss of EUR 0.42 per share​

* Proqr Therapeutics Nv - ‍net result for three month period ended September 30, 2017 was a EUR 10.5 million loss or EUR 0.42 per share​ Source text for Eikon: Further company coverage:

20 Nov 2017

BRIEF-ProQR doses first LCA 10 patient in clinical trial of QR-110

* ProQR doses first LCA 10 patient in clinical trial of qr-110, ProQR's lead program for genetic blindness

13 Nov 2017

BRIEF-JDG B.V. reports 10.5 pct passive stake in ProQR Therapeutics NV as on Sept 14

* JDG B.V. Reports 10.5 percent passive stake in ProQR Therapeutics NV as on September 14 - SEC Filing‍​ Source text: (http://bit.ly/2yhtqSA) Further company coverage:

12 Oct 2017

BRIEF-ProQR announces positive top-line results from a phase 1b study of QR-010

* ProQR announces positive top-line results from a Phase 1b study of QR-010 in subjects with Cystic Fibrosis

26 Sep 2017

BRIEF-ProQR gets orphan drug designation from FDA for drug candidate QR-313

* ProQR receives orphan drug designation from FDA for drug candidate QR-313 for dystrophic epidermolysis bullosa and will present data at two scientific conferences

19 Sep 2017

BRIEF-ProQR Therapeutics spins out Amylon Therapeutics

* ProQR therapeutics - spun out Amylon Therapeutics, a privately-held company focused on development of therapies for central nervous system disorders

12 Sep 2017

BRIEF-ProQR Q2 loss per share EUR 0.47

* ProQR Therapeutics - enrollment completed in phase 1b clinical trial in cystic fibrosis (CF) and top-line data expected to be announced in September Source text for Eikon: Further company coverage:

16 Aug 2017

Earnings vs. Estimates